Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate's novel monoclonal antibody, to be manufactured with Vivalis' EB66® platform, for rare cutaneous cancers.
| PR in english | 42.01 KB |
| CP en français | 42.88 KB |